



CIN No. L24232PB1983PLC005426

GST No. 03AAACK6458M1ZB

D.L. No. 1800-OSP, 1804-B

I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LIMITED

Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
 : 91-8558820863 (Admin.)
 : 91-9915743720 (Exports)
 M.D. Mobile : 91-9814071215, 9814052314
 E-mail : export@kwalitypharma.com
 ramesh@kwalitypharma.com

To
 The BSE Limited
 Department of Corporate Services,
 P.J. Towers, Dalal Street,
 Mumbai-400001

Date: 29th April, 2024

Subject: Announcement under Regulation 30 of SEBI (listing Obligations and Disclosure Requirements), Regulations, 2015 - KWALITY PHARMA RECEIVED INVIMA APPROVAL FOR ITS ONCOLOGY (UNIT-III) VIAL LINE AND TABLET LINE

Dear Sir/Madam,

We are pleased to announce that Company's finished dosage form manufacturing facility, Oncology Injectable unit at Himachal Pradesh has received the approval (inspection from 21st April to 25th April, 2024) from the Columbian Drug Regulatory Authority - **INVIMA** (INVIMA is the National Institute for the surveillance of Drugs and Food designated by the Columbian Ministry of the Social Protection) for below mentioned categories:

Old Production line	Dosage Form		Capacity	
			Liquid	lyophilized
Vial	Liquid solution lyophilized for injections	Two lyophilized for small batches	30,000 (per day)	15000 (per 4 days)
Tablet	coated + uncoated		2,00,000 (per day)	

New Production line	Dosage Form		Capacity	
			Liquid	lyophilized
Vial	Liquid solution lyophilized for injections	For large batches	10,000 (per day)	30,000 (per 4 days)

The approval grants access to the Company to register and market its products at the large and growing Colombian Pharmaceutical Market.

This is for your information, records and meeting the disclosure requirements under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Thanking You,

For Kwality Pharmaceuticals Limited


Ramesh Arora
 Managing Director
 DIN: 00462656

